Civic Intelligence

Juvenile Bipolar Research Foundation Inc

990EZ • Fiscal year 2019 • EIN 16-1612095

Jan 01, 2019 to Dec 31, 2019 • Filed on Nov 11, 2020

Organization Profilewww.jbrf.org
277 Martine AvenueWhite Plains, NY 10601

(914) 468-1297

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

70th percentile

0.03x

Higher debt load relative to assets than 70% of similar nonprofits.

2019 filings • 501(c)3 • <$500k nonprofits • Source year 2019

Liabilities / Revenue

90th percentile

0.33x

Higher debt load relative to revenue than 90% of similar nonprofits.

2019 filings • 501(c)3 • <$500k nonprofits • Source year 2019

Net Margin

2nd percentile

-421%

Higher net margin than 2% of similar nonprofits.

2019 filings • 501(c)3 • <$500k nonprofits • Source year 2019

Top Officer Pay

77th percentile

$0

Higher top officer pay than 77% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

2019 filings • 501(c)3 • <$500k nonprofits • Source year 2019

Asset Growth

18th percentile

-25%

Faster asset growth than 18% of similar nonprofits.

2019 filings • 501(c)3 • <$500k nonprofits • Annualized from 2018 to 2019

Revenue Growth

49th percentile

0.5%

Faster revenue growth than 49% of similar nonprofits.

2019 filings • 501(c)3 • <$500k nonprofits • Annualized from 2018 to 2019

Balance Sheet
Liabilities / Assets70th percentile

Assets

Down

$424,451

Down $143,052 (-25%) from 2018

Net Assets

Down

$411,939

Down $153,912 (-27%) from 2018

Liabilities

Up

$12,512

Up $10,860 (+657%) from 2018

Revenue And Expenses
Liabilities / Revenue90th percentileNet Margin2nd percentile

Revenue

Up

$38,369

Up $204 (+0.5%) from 2018

Expenses

Up

$199,878

Up $67,430 (+51%) from 2018

Net Income

Down

-$161,509

Down $67,226 (-71%) from 2018

Historical Trend

Balance Sheet Trend

Asset Growth18th percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$1.5M$1.0M$500K$0Assets 2010: $535,417Liabilities 2010: $8,300Net Assets 2010: $527,1172010Assets 2011: $691,681Liabilities 2011: $8,300Net Assets 2011: $683,3812011Assets 2012: $413,429Liabilities 2012: $8,300Net Assets 2012: $405,1292012Assets 2013: $1,037,428Liabilities 2013: $3,905Net Assets 2013: $1,033,5232013Assets 2014: $1,037,388Liabilities 2014: $8,519Net Assets 2014: $1,028,8692014Assets 2015: $949,065Liabilities 2015: $5,543Net Assets 2015: $943,5222015Assets 2016: $835,285Liabilities 2016: $3,128Net Assets 2016: $832,1572016Assets 2017: $665,847Liabilities 2017: $2,723Net Assets 2017: $663,1242017Assets 2018: $567,503Liabilities 2018: $1,652Net Assets 2018: $565,8512018Assets 2019: $424,451Liabilities 2019: $12,512Net Assets 2019: $411,9392019Assets 2020: $165,683Liabilities 2020: $299Net Assets 2020: $165,3842020Assets 2021: $373,670Liabilities 2021: $257Net Assets 2021: $373,4132021Assets 2022: $188,175Liabilities 2022: $57Net Assets 2022: $188,1182022

Highlighted filing

2019

Assets$424,451
Liabilities$12,512
Net Assets$411,939
Open 2019 Filing

Operations Trend

Revenue Growth49th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$1.0M$500K$0-$500KRevenue 2010: $439,705Expenses 2010: $347,959Net Income 2010: $91,7462010Revenue 2011: $521,271Expenses 2011: $365,007Net Income 2011: $156,2642011Revenue 2012: $111,029Expenses 2012: $389,281Net Income 2012: -$278,2522012Revenue 2013: $839,222Expenses 2013: $210,828Net Income 2013: $628,3942013Revenue 2014: $120,960Expenses 2014: $134,490Net Income 2014: -$13,5302014Revenue 2015: $46,668Expenses 2015: $124,512Net Income 2015: -$77,8442015Revenue 2016: $39,963Expenses 2016: $152,737Net Income 2016: -$112,7742016Revenue 2017: $41,967Expenses 2017: $213,140Net Income 2017: -$171,1732017Revenue 2018: $38,165Expenses 2018: $132,448Net Income 2018: -$94,2832018Revenue 2019: $38,369Expenses 2019: $199,878Net Income 2019: -$161,5092019Revenue 2020: $95,907Expenses 2020: $333,747Net Income 2020: -$237,8402020Revenue 2021: $383,576Expenses 2021: $184,193Net Income 2021: $199,3832021Revenue 2022: $63,950Expenses 2022: $249,245Net Income 2022: -$185,2952022

Highlighted filing

2019

Revenue$38,369
Expenses$199,878
Net Income-$161,509
Open 2019 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2019 to Dec 31, 2019
Signed
Nov 11, 2020
Return Version
2019v5.0
Gross Receipts
$38,369
Mission and Program Overview

Mission

JBRF supports children and families sufferning from bipolar disorder and fear of harm through research, education, and outreach

TO RAISE AND DISTRIBUTE FUNDS FOR THE MOST PROMISING RESEARCH INTO THE CAUSES, TREATMENT AND PREVENTION OF EARLY-ONSET BIPOLAR DISORDER. In particular, we aim to further investigate and promote awareness of the fear of harm phenotype which our research has identified as being simultaneously associated with a distinct biomaker as well as the symptoms of childhood-onset bipolar disorder.

Program Services

DescriptionGrantsExpenses
Research An fMRI Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults with Bipolar Disorder Fear of Harm Phenotype proposed by Martin Teicher, M.D. Ph.D of Harvard Medical School has been peer reviewed and was approved for funding by the board. The study is planned to get underway in late spring 2018 following approval of the Harvard IRB. A proposal for the development of induced pluripotent stem cells in patients with FOH phenotype by Herb Lachman, MD the Albert Einstein College of Medicine Department of Psychiatry, Department of Neuroscience and Department of Genetics has been submitted for review. The study proposes to generate iPS cells to study the Fear of Harm (FOH) subgroup of bipolar disorder (BD) that is characterized by separation anxiety, circadian rhythm problems, parasomnias and thermoregulatory dysfunction. The iPS cells will be prepared from patients with FOH, BD without FOH, and matched controls. These will be induced to differentiate into hypothalamic neurons and cortical neurons that express the NMDA receptor, which is activated by the neurotransmitter glutamate. The focus on the hypothalamus and the NMDA receptor is duethe distinctive clinical and pharmacological characteristics of FOH. The hypothalamus is the brain structure that controls thermoregulation, sleep, and circadian rhythms, which are uniquely disrupted in FOH; the NMDA receptor is the primary target of ketamine, which dramatically reduces symptoms in most patients. The different types of neurons to be cultivated will be analyzed by a variety of means, including transcriptome analysis using RNA-seq a state of the art method for assessing the activity level of every gene in the genome, which is a powerful tool for understanding underlying disease mechanisms.This proposal has been preliminarily approved but awaits funding.The research paper, Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype, was accepted and has been published in Journal of Affective Disorders. See https://www.jbrf.org/wp-content/uploads/KetamineFOHLongitudinalStudyPub.pdfAn abstract of the paper follows:AbstractObjectives: Fear of Harm (FOH) is a pediatric onset phenotype of bipolar disorder (BD) characterized by BD plus treatment resistance, separation anxiety, aggressive obsessions, parasomnias, and thermal dysregulation. Intranasal ketamine (IK) in 12 youths with BD-FOH produced marked improvement during a two-week trial. Here we report on the open effectiveness and safety of IK in maintenance treatment of BD-FOH from the private practice of one author.Methods: As part of a chart review, patients 18 years or older and parents of younger children responded to a clinical effectiveness and safety survey. Effectiveness was assessed from analysis of responses to 49 questions on symptomatology plus qualitative content analyses of written reports and chart review. Adverse events (AEs) were analyzed by frequency, duration and severity. Results: Surveys were completed on 45 patients treated with IK for 3 months to 6.5 years. Almost all patients were much to very much improved clinically and in ratings of social function and academic performance. Significant reductions were reported in all symptom categories. There were 13 reports of persistent AEs, none of which resulted in discontinuation. Acute emergence reactions were sporadically observed in= up to 75%, but were mild and of brief duration. Limitations: Retrospective review from a single practice without placebo control with potential for response and recall bias. Conclusions: IK every 3-4 days at sub-anaesthetic doses appeared to be a beneficial and well-tolerated treatment. Use of IK may be considered as a tertiary alternative in treatment refractory cases. Randomized control trials are warranted.$56,051-
Compensation and Service Providers
Top Officer Pay77th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
JOHN COSENTINO JRDirector-$0--
DR STEVEN MATTISPresident-$0--
JAMES BRAGGDirector-$0--
DR HERBERT LACHMANDirector-$0--
DR DEMITRI PAPOLOSResearch Direct-$0--
JOHN BERNARDOTreasurer-$0--
SARAH BOWMANDirector-$0--
Filing and Contact Details

Filer

Filer Name
Juvenile Bipolar Research Foundation Inc
EIN
16-1612095
Phone
9144681297
Address
277 MARTINE AVENUE, WHITE PLAINS, NY 10601

Signing Officer

Name
Dr Steven Mattis
Title
President
Signed
2020-11-11
Discuss with paid preparer
Yes

Preparer

Firm
Berard & Associates CPAs PC
Address
44 Park Ave, Suffern, NY 10901
Preparer
Donalee R Berard
Phone
8453575668
Supplemental Narrative

Additional Explanations

Other Expenses.1005

“Travel $2702”

Other Expenses.1012

“Insurance $5480”

Other Expenses.1

“CONSULTING FEES $32369”

Other Expenses.2

“RESEARCH EXPENSE $24158”

Other Expenses.3

“OFFICE SERVICE $9777”

Other Expenses.4

“MEMBERSHIP FEES $9264”

Other Expenses.5

“Fundraising & marketing $7265”

Other Expenses.7

“Board member expenses $208”

Other Expenses.8

“OFFICE SUPPLIES $64”

Other Expenses.9

“BANK CHARGES $62”

Other Assets.1005

“Accounts Receivable - Beginning $781 Accounts Receivable - Ending $4166”

Other Assets.1011

“Prepaid Expenses and Deferred Charges - Beginning $1379 Prepaid Expenses and Deferred Charges - Ending $633”

Other Assets.1

“- Beginning $1300 - Ending $1300”

Total Liabilities.1001

“Accounts Payable and Accrued Expenses - Beginning $1652 Accounts Payable and Accrued Expenses - Ending $12512”

Raw XML Appendix194 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0TAXPAYER-914-468-1297
IRS990EZ/BooksInCareOfDetail/PhoneNum09144681297
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt0277 MARTIN AVENUE-STE 226
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0WHITE PLAINS
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0NY
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd010601
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt0564043
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt0418352
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt037079
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-161509
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt08288
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt0567503
IRS990EZ/Form990TotalAssetsGrp/EOYAmt0424451
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GrossReceiptsAmt038369
IRS990EZ/InfoInScheduleOPartIIInd0X
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InvestmentIncomeAmt01290
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingAccrualInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt0565851
IRS990EZ/NetAssetsOrFundBalancesEOYAmt0411939
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt0565851
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt0411939
IRS990EZ/OccupancyRentUtltsAndMaintAmt09135
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt01.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt12.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt22.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt32.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt42.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt52.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt62.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt60
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0JOHN COSENTINO JR
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1DR STEVEN MATTIS
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2JAMES BRAGG
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3DR HERBERT LACHMAN
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4DR DEMITRI PAPOLOS
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5JOHN BERNARDO
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm6SARAH BOWMAN
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1President
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4RESEARCH DIRECT
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5Treasurer
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt6Director
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherAssetsTotalDetail/BOYAmt03460
IRS990EZ/OtherAssetsTotalDetail/EOYAmt06099
IRS990EZ/OtherChangesInNetAssetsAmt07597
IRS990EZ/OtherExpensesTotalAmt091349
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0TO RAISE AND DISTRIBUTE FUNDS FOR THE MOST PROMISING RESEARCH INTO THE CAUSES, TREATMENT AND PREVENTION OF EARLY-ONSET BIPOLAR DISORDER. In particular, we aim to further investigate and promote awareness of the fear of harm phenotype which our research has identified as being simultaneously associated with a distinct biomaker as well as the symptoms of childhood-onset bipolar disorder.
IRS990EZ/PrintingPublicationsPostageAmt04721
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0Research An fMRI Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults with Bipolar Disorder Fear of Harm Phenotype proposed by Martin Teicher, M.D. Ph.D of Harvard Medical School has been peer reviewed and was approved for funding by the board. The study is planned to get underway in late spring 2018 following approval of the Harvard IRB. A proposal for the development of induced pluripotent stem cells in patients with FOH phenotype by Herb Lachman, MD the Albert Einstein College of Medicine Department of Psychiatry, Department of Neuroscience and Department of Genetics has been submitted for review. The study proposes to generate iPS cells to study the Fear of Harm (FOH) subgroup of bipolar disorder (BD) that is characterized by separation anxiety, circadian rhythm problems, parasomnias and thermoregulatory dysfunction. The iPS cells will be prepared from patients with FOH, BD without FOH, and matched controls. These will be induced to differentiate into hypothalamic neurons and cortical neurons that express the NMDA receptor, which is activated by the neurotransmitter glutamate. The focus on the hypothalamus and the NMDA receptor is duethe distinctive clinical and pharmacological characteristics of FOH. The hypothalamus is the brain structure that controls thermoregulation, sleep, and circadian rhythms, which are uniquely disrupted in FOH; the NMDA receptor is the primary target of ketamine, which dramatically reduces symptoms in most patients. The different types of neurons to be cultivated will be analyzed by a variety of means, including transcriptome analysis using RNA-seq a state of the art method for assessing the activity level of every gene in the genome, which is a powerful tool for understanding underlying disease mechanisms.This proposal has been preliminarily approved but awaits funding.The research paper, Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype, was accepted and has been published in Journal of Affective Disorders. See https://www.jbrf.org/wp-content/uploads/KetamineFOHLongitudinalStudyPub.pdfAn abstract of the paper follows:AbstractObjectives: Fear of Harm (FOH) is a pediatric onset phenotype of bipolar disorder (BD) characterized by BD plus treatment resistance, separation anxiety, aggressive obsessions, parasomnias, and thermal dysregulation. Intranasal ketamine (IK) in 12 youths with BD-FOH produced marked improvement during a two-week trial. Here we report on the open effectiveness and safety of IK in maintenance treatment of BD-FOH from the private practice of one author.Methods: As part of a chart review, patients 18 years or older and parents of younger children responded to a clinical effectiveness and safety survey. Effectiveness was assessed from analysis of responses to 49 questions on symptomatology plus qualitative content analyses of written reports and chart review. Adverse events (AEs) were analyzed by frequency, duration and severity. Results: Surveys were completed on 45 patients treated with IK for 3 months to 6.5 years. Almost all patients were much to very much improved clinically and in ratings of social function and academic performance. Significant reductions were reported in all symptom categories. There were 13 reports of persistent AEs, none of which resulted in discontinuation. Acute emergence reactions were sporadically observed in= up to 75%, but were mild and of brief duration. Limitations: Retrospective review from a single practice without placebo control with potential for response and recall bias. Conclusions: IK every 3-4 days at sub-anaesthetic doses appeared to be a beneficial and well-tolerated treatment. Use of IK may be considered as a tertiary alternative in treatment refractory cases. Randomized control trials are warranted.
IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt056051
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/SalariesOtherCompEmplBnftAmt086385
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0NJ
IRS990EZ/StatesWhereCopyOfReturnIsFldCd1NY
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt01652
IRS990EZ/SumOfTotalLiabilitiesGrp/EOYAmt012512
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt0199878
IRS990EZ/TotalProgramServiceExpensesAmt056051
IRS990EZ/TotalRevenueAmt038369
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0www.jbrf.org
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt037079
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt036944
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt040743
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt037643
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt045267
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt0197676
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/TotalAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt01290
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt01221
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt01224
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus3YearsAmt02320
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt01378
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt07433
IRS990ScheduleA/OtherIncome170Grp/TotalAmt00
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.84530
IRS990ScheduleA/PublicSupportPY170Pct00.65180
IRS990ScheduleA/PublicSupportTotal170Amt0173380
IRS990ScheduleA/SubstantialContributorsTotAmt024296
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/TotalAmt00
IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt037079
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt036944
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt040743
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt037643
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt045267
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt0197676
IRS990ScheduleA/TotalSupportAmt0205109
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/TotalAmt00
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Travel $2702
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1Insurance $5480
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2CONSULTING FEES $32369
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3RESEARCH EXPENSE $24158
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4OFFICE SERVICE $9777
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt5MEMBERSHIP FEES $9264
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt6FUNDRAISING & MARKETING $7265
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt7BOARD MEMBER EXPENSES $208
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt8OFFICE SUPPLIES $64
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt9BANK CHARGES $62
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt10Accounts Receivable - Beginning $781 Accounts Receivable - Ending $4166
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt11Prepaid Expenses and Deferred Charges - Beginning $1379 Prepaid Expenses and Deferred Charges - Ending $633
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt12- Beginning $1300 - Ending $1300
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt13Accounts Payable and Accrued Expenses - Beginning $1652 Accounts Payable and Accrued Expenses - Ending $12512
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Other Expenses.1005
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Other Expenses.1012
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2Other Expenses.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3Other Expenses.2
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4Other Expenses.3
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc5Other Expenses.4
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc6Other Expenses.5
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc7Other Expenses.7
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc8Other Expenses.8
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc9Other Expenses.9
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc10Other Assets.1005
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc11Other Assets.1011
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc12Other Assets.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc13Total Liabilities.1001
ReturnHeader/BuildTS02021-01-29 14:40:06Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0DR STEVEN MATTIS
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0President
ReturnHeader/BusinessOfficerGrp/SignatureDt02020-11-11
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0JUVENILE BIPOLAR RESEARCH FOUNDATION INC
ReturnHeader/Filer/BusinessNameControlTxt0JUVE
ReturnHeader/Filer/EIN0161612095
ReturnHeader/Filer/PhoneNum09144681297
ReturnHeader/Filer/USAddress/AddressLine1Txt0277 MARTINE AVENUE
ReturnHeader/Filer/USAddress/CityNm0WHITE PLAINS
ReturnHeader/Filer/USAddress/StateAbbreviationCd0NY
ReturnHeader/Filer/USAddress/ZIPCd010601
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0133774222
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0Berard & Associates CPAs PC
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt044 Park Ave
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0Suffern
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0NY
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd010901
ReturnHeader/PreparerPersonGrp/PhoneNum08453575668
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0DONALEE R BERARD
ReturnHeader/PreparerPersonGrp/SelfEmployedInd0X
ReturnHeader/ReturnTs02020-11-11T11:52:00-08:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02019-01-01
ReturnHeader/TaxPeriodEndDt02019-12-31
ReturnHeader/TaxYr02019

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2019 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$424,451
Liabilities
$12,512
Net assets
$411,939
Revenue
$38,369
Expenses
$199,878
Net income
-$161,509
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2022XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.19$0.00$0.19$0.06$0.25$0.19
2021XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.37$0.00$0.37$0.38$0.18$0.20
2020XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.17$0.00$0.17$0.10$0.33$0.24
2019Detailed filing. Detailed filing data is available for this year.$0.42$0.01$0.41$0.04$0.20$0.16
2018Detailed filing. Detailed filing data is available for this year.$0.57$0.00$0.57$0.04$0.13$0.09
2017XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.67$0.00$0.66$0.04$0.21$0.17
2016XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.84$0.00$0.83$0.04$0.15$0.11
2015XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.95$0.01$0.94$0.05$0.12$0.08
2014Detailed filing. Detailed filing data is available for this year.$1.04$0.01$1.03$0.12$0.13$0.01
2013XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$1.04$0.00$1.03$0.84$0.21$0.63
2012Summary only. Only limited summary data is available for this year.$0.41$0.01$0.41$0.11$0.39$0.28
2011Summary only. Only limited summary data is available for this year.$0.69$0.01$0.68$0.52$0.37$0.16
2010Summary only. Only limited summary data is available for this year.$0.54$0.01$0.53$0.44$0.35$0.09